TerminatedPhase 1NCT01440192

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

Studying Sarcoidosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Celularity Incorporated
Principal Investigator: Monica E Luchi, MD
Celularity Incorporated
Intervention: PDA001 (cenplacel-L)(biological)
Enrollment: 4 target
Eligibility: 18-75 years · All sexes
Timeline: 2011 – 2014

Study locations (4)

University of Alabama, Birmingham - Division of Pulmonary, Allergy, and Critical Care Medicine, Birmingham, Alabama, United States
National Jewish Health, Denver, Colorado, United States
University of Cincinatti Medical Center, Cincinnati, Ohio, United States
The Cleveland Clinic Foundation - Respiratory Institute, Cleveland, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01440192 on ClinicalTrials.gov

Other trials for Sarcoidosis

Additional recruiting or active studies for the same condition.

See all trials for Sarcoidosis →

← Back to all trials